Liu Yafeng, Han Zhaojin, Li Yujia, Zhang Pengfei, Wang Qiushi
Department of Thoracic Surgery, Second Affiliated Hospital of Harbin Medical University, Harbin, China.
Front Pharmacol. 2025 Aug 15;16:1665174. doi: 10.3389/fphar.2025.1665174. eCollection 2025.
Lung cancer remains the leading cause of cancer-related incidence and mortality worldwide. Non-small cell lung cancer (NSCLC) constitutes the most prevalent histological subtype of lung cancer. A notable proportion of NSCLC patients harbor mutations in the anaplastic lymphoma kinase (ALK) gene, and treatment with ALK-TKIs has demonstrated favorable therapeutic efficacy in ALK-positive patients. This study aimed to systematically analyze the body of literature on ALK-TKIs in NSCLC over the past decade from a bibliometric perspective.
Relevant literature on anaplastic ALK-TKIs for the treatment of NSCLC published between 2015 and 2024 was retrieved from the Web of Science Core Collection. Only English-language publications categorized as original researches and reviews were included. Additionally, clinical trial data from the past decade were collected from the ClinicalTrials.gov database. Bibliometric analysis, data processing, and visualization were conducted using CiteSpace, VOSviewer, Excel, and R.
Between 2015 and 2024, a total of 2,877 publications on ALK-TKIs for NSCLC were identified, with the annual output remaining consistently high, and 198 clinical trials were registered on ClinicalTrials.gov. China contributed the highest number of publications, while Massachusetts General Hospital emerged as the most prolific institution. The most influential journal in this field was , and Alice T. Shaw was both the most prolific and one of the most influential authors. Keywords such as 'lorlatinib', 'resistance', 'circulating tumor DNA', and 'immunotherapy', along with keyword clustering, indicate current research hotspots and future directions in this field.
This study provides a comprehensive bibliometric analysis and summary of the developmental trajectory, current research landscape, and future trends in ALK-TKI therapy for NSCLC over the past decade, with individualized and precision medicine remaining the primary direction for the development of ALK-TKI therapy in NSCLC.
肺癌仍然是全球癌症相关发病率和死亡率的主要原因。非小细胞肺癌（NSCLC）是肺癌中最常见的组织学亚型。相当一部分NSCLC患者的间变性淋巴瘤激酶（ALK）基因存在突变，ALK酪氨酸激酶抑制剂（ALK-TKIs）治疗已在ALK阳性患者中显示出良好的治疗效果。本研究旨在从文献计量学角度系统分析过去十年中关于NSCLC中ALK-TKIs的文献。
从Web of Science核心合集中检索2015年至2024年间发表的关于用于治疗NSCLC的间变性ALK-TKIs的相关文献。仅纳入分类为原始研究和综述的英文出版物。此外，从ClinicalTrials.gov数据库收集过去十年的临床试验数据。使用CiteSpace、VOSviewer、Excel和R进行文献计量分析、数据处理和可视化。
2015年至2024年间，共鉴定出2877篇关于NSCLC的ALK-TKIs的出版物，年产量一直很高，并且在ClinicalTrials.gov上注册了198项临床试验。中国的出版物数量最多，而麻省总医院是最多产的机构。该领域最具影响力的期刊是 ，艾丽斯·T·肖既是最多产的作者之一，也是最具影响力的作者之一。“洛拉替尼”“耐药性”“循环肿瘤DNA”和“免疫疗法”等关键词以及关键词聚类表明了该领域当前的研究热点和未来方向。
本研究对过去十年NSCLC的ALK-TKI治疗的发展轨迹、当前研究状况和未来趋势进行了全面的文献计量分析和总结，个体化和精准医学仍然是NSCLC中ALK-TKI治疗发展的主要方向。
Zotero 插件
